Shares of Immatics (NASDAQ:IMTX – Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $11.07, but opened at $10.33. Immatics shares last traded at $9.93, with a volume of 406,903 shares traded.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on IMTX. Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a research report on Thursday, September 5th. Piper Sandler began coverage on shares of Immatics in a report on Monday, October 7th. They set an “overweight” rating and a $19.00 price objective for the company.
Read Our Latest Analysis on Immatics
Immatics Stock Performance
Immatics (NASDAQ:IMTX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.17. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. The company had revenue of $20.19 million for the quarter, compared to analysts’ expectations of $12.36 million. On average, equities analysts predict that Immatics will post -0.94 earnings per share for the current year.
Institutional Trading of Immatics
A number of institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC lifted its stake in shares of Immatics by 76.5% during the 2nd quarter. Perceptive Advisors LLC now owns 8,086,159 shares of the company’s stock worth $93,961,000 after acquiring an additional 3,503,750 shares during the last quarter. RA Capital Management L.P. bought a new position in Immatics in the first quarter worth approximately $18,392,000. Goldman Sachs Group Inc. increased its holdings in Immatics by 324.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock worth $16,310,000 after purchasing an additional 1,183,860 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in shares of Immatics in the 2nd quarter worth $13,392,000. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Immatics by 38.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock worth $33,899,000 after buying an additional 891,191 shares in the last quarter. 64.41% of the stock is currently owned by institutional investors.
Immatics Company Profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Stories
- Five stocks we like better than Immatics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- How to Plot Fibonacci Price Inflection Levels
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Following Congress Stock Trades
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.